MetaCap

NovaBridge Biosciences ADR (NBP)

NASDAQ: NBPHealth CareBiotechnology: Pharmaceutical PreparationsUSD

0.83-0.0498 (-5.66%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

NBP stock chart

Technical analysis

Key statistics

All statistics
Market cap
$96.28M
EPS (TTM)
-$0.69
52-week range
0.751 – 5.19
Day range
0.825 – 0.9803
Volume / Avg
991.51K / 515.66K
Beta
—

52-week range

$0.751$5.19

NBP stock today

NovaBridge Biosciences (NBP) closed at $0.83 on Nov 20, down 5.66% (-$0.0498), versus the S&P 500's 3.70% decline. At this level, NBP sits near the bottom of its 52-week range of $0.751 to $5.19: 84.0% below the high, set on Jan 6, 2026 and 10.5% above the low. NBP is down 79.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 80.4%.

NovaBridge Biosciences has posted a net loss over the last twelve months (EPS of -$0.69), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About NovaBridge Biosciences

Company profile

NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology. Its product pipeline comprises givastomig, a potential CLDN18.2 bispecific antibody, which is in phase 2 clinical trial combination with nivolumab and chemotherapy for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies; Phase 1b clinical trial in combination with nivolumab and chemotherapy in first-line gastric cancer.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Srishti Gupta M.D.
Headquarters
Rockville, MD
Employees
30
IPO year
2020

Financial highlights

Full financials

NovaBridge Biosciences reported a net loss of $46.3 million, compared with a loss of $22.2 million a year earlier. Diluted earnings per share came in at -$0.21.

NovaBridge Biosciences annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue——$632.00K$-1.55M$13.81M
Growth——+140.75%-111.23%-94.16%
Net income$-46.27M$-22.23M$-207.73M$-371.05M$-365.87M
EPS (diluted)$-0.21$-0.12$-1.09$-1.96$-2.09

Analyst forecast

Forecast

Consensus (3 analysts)

strong_buy

Avg. price target

$8.67+944.58%

  • Strong buy 0
  • Buy 3
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $8.00High $9.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

NBP news

All NBP news

NovaBridge Biosciences peers

Health Care sector
NBP peer companies
CompanyPrice% ChgMarket capCompare
PDSBPDS Biotechnology Corporation0.7774-3.70%$95.39Mvs NBP
NRXPNRX Pharmaceuticals Inc.2.15-15.69%$95.31Mvs NBP
UNCYUnicycive Therapeutics Inc.3.35-5.10%$97.77Mvs NBP
CNTNCanton Strategic Holdings Inc.1.21-1.63%$98.78Mvs NBP
DERMJourney Medical Corporation3.30-7.04%$93.16Mvs NBP
NERVMinerva Neurosciences Inc2.00-5.66%$99.67Mvs NBP
CLLSCellectis S.A. ADR0.9209-7.89%$92.76Mvs NBP
ORGOOrganogenesis Holdings Inc. Class A0.7716-2.23%$100.16Mvs NBP

Indexes, lists and sector

NovaBridge Biosciences stock FAQ

What is NovaBridge Biosciences's stock price today?

NBP last traded at $0.83 as of Nov 20, 4:00 PM EST, down 5.66% on the day. Prices are delayed at least 15 minutes.

Who is NovaBridge Biosciences's CEO?

Dr. Srishti Gupta M.D. is the chief executive officer of NovaBridge Biosciences ADR, which has about 30 employees.

What is the NBP 52-week high?

The 52-week high for NBP is $5.19 and the 52-week low is $0.751. The stock is currently 84.0% below its high.

Compare NBP